Solana Company Q4 FY2023 Earnings Call

· Earnings call transcript and AI-powered summary

Overview
  • Date of Call: March 28, 2024
  • Company Focus: Gaining widespread reimbursement and FDA stroke approval for the PoNS (Portable Neuromodulation Stimulator) device
  • Current U.S. Authorization: Treatment of gait deficit due to mild-to-moderate symptoms from MS
Key Operational Highlights
  • HCPCS Code Assignment: Unique HCPCS codes granted for PoNS controller and mouthpiece effective April 1, 2024; enables Helius to begin reimbursement negotiations and submit insurance claims.
  • Reimbursement Milestone: Targeting Medicare reimbursement decision by October 1, 2024.
  • PoNS Step Study: Real-world MS adherence trial, primary endpoint data expected in Q3 2024; preliminary results anticipated before year-end.
  • VA Targeting: Initiated engagement with U.S. Department of Veterans Affairs, aiming to penetrate care for the 28,000+ MS cases reported annually within the VA system.
  • Stroke Therapy Progress: FDA alignment on development plan for stroke indication, leveraging a randomized controlled study and open-label trial. Target regulatory submission in early 2025 and possible U.S. market authorization by late 2025.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good day, and thank you for standing by, and welcome to Helius Medical Technologies, Inc. Q4 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Michelle Bilski, In-Site Communications. Please go ahead. Michelle Bilski: Thank you, operator. Welcome to the fourth quarter 2023 earnings conference call for Helius Medical Technologies. This is Michelle Bilski of In-Site Communications, Investor Relations for Helius. With me on today's call are Dane Andreeff, Helius Medical's President and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer. At this time all participants have been placed in a listen-only mode. Please note that this call is being recorded and access to the webcast can be obtained through the Investors section of the Helius website at www.heliusmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicating, including those identified in the Risk Factors section of our most recent an

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional